ReviewCells2021
Molecular Markers and Targets in Melanoma.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06710093 (Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma), which is not on this map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 198 citations in OpenAlex.
- New Primary and Secondary Prevention Measures for Cutaneous Melanoma: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial.Journal of translational medicine · 2025Trial
- Review
- Mucosal melanoma in 1481 patients in the Netherlands. An overview of metastatic patterns, main driver mutations and the efficacy of therapeutic strategies.BJC reports · 2026Article
- Targeting MAPK Pathways in Skin, Thyroid, and Pancreatic Cancer: A Perspective on Synthetic Inhibitors and Natural Modulators.Advanced biology · 2026Review
- Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026Review
- Antitumor Effect of Ruthenium(II) with 2‑Mercaptothiazoline Ligand Complex in Murine Melanoma Model.ACS omega · 2026Article
- Integrated Metabolomics, Network Pharmacology, and Molecular Dynamics Simulations Reveal the Potential Anti-Melanoma Mechanisms ofCurrent issues in molecular biology · 2026Article
- Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Novel C3/C28-bis-1,2,4-Triazolyl-sulfanylacetate-betulin Derivatives: Synthesis and Evaluation of Anticancer Potential.International journal of molecular sciences · 2026Article
- Genetics and Molecular Mechanisms in Oral Squamous Cell Carcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- The Effects of Sun Exposure and Pigmentation Phenotype on Prognosis in Metastatic Melanoma.Acta dermato-venereologica · 2026Article
- Regulation and Implementation of Apoptosis in Melanoma Tumor Cells withCurrent issues in molecular biology · 2026Review
- A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAFAntibodies (Basel, Switzerland) · 2026Article
- Article
- Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma.Clinical and experimental dermatology · 2026Article
- Innovations in Cutaneous Oncology and Dermatologic Surgery: From Margin Control to Integrated Precision Oncology.Cancers · 2026Review
- Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy.Molecules (Basel, Switzerland) · 2026Review
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma develops as a result of several genetic alterations, with UV radiation often acting as a mutagenic risk factor. Deep knowledge of the molecular signaling pathways of different types of melanoma allows better characterization and provides tools for the development of therapies based on the intervention of signals promoted by these cascades. The latest World Health Organization classification acknowledged the specific genetic drivers leading to melanoma and classifies melanocytic lesions into nine distinct categories according to the associate cumulative sun damage (CSD), which correlates with the molecular alterations of tumors. The largest groups are melanomas associated with low-CSD or superficial spreading melanomas, characterized by frequent presentation of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.